Literature DB >> 33416459

Caveolin-3 is required for regulation of transient outward potassium current by angiotensin II in mouse atrial myocytes.

Leonid Tyan1, Daniel Turner1, Karlie R Komp1, Roman Y Medvedev1, Evi Lim1, Alexey V Glukhov1.   

Abstract

Angiotensin II (AngII) is a key mediator of the renin-angiotensin system and plays an important role in the regulation of cardiac electrophysiology by affecting various cardiac ion currents, including transient outward potassium current, Ito. AngII receptors and molecular components of Ito, Kv4.2 and Kv4.3 channels, have been linked to caveolae structures. However, their functional interaction and the importance of such proximity within 50- to 100-nm caveolar nanodomains remain unknown. To address this, we studied the mechanisms of Ito regulation by AngII in atrial myocytes of wild-type (WT) and cardiac-specific caveolin-3 (Cav3) conditional knockout (Cav3KO) mice. We showed that in WT atrial myocytes, a short-term (2 h) treatment with AngII (5 µM) significantly reduced Ito density. This effect was prevented 1) by a 30-min pretreatment with a selective antagonist of AngII receptor 1 (Ang1R) losartan (2 µM) or 2) by a selective inhibition of protein kinase C (PKC) by BIM1 (10 µM). The effect of AngII on Ito was completely abolished in Cav3-KO mice, with no change in a baseline Ito current density. In WT atria, Ang1Rs co-localized with Cav3, and the expression of Ang1Rs was significantly decreased in Cav3KO in comparison with WT mice, whereas no change in Kv4.2 and Kv4.3 protein expression was observed. Overall, our findings demonstrate that Cav3 is involved in the regulation of Ang1R expression and is required for the modulation of Ito by AngII in mouse atrial myocytes.NEW & NOTEWORTHY Angiotensin II receptor 1 is associated with caveolae and caveolar scaffolding protein caveolin-3 in mouse atrial myocytes that is required for the regulation of Ito by angiotensin II. Downregulation of caveolae/caveolin-3 disrupts this regulation and may be implicated in pathophysiological atrial remodeling.

Entities:  

Keywords:  angiotensin II; angiotensin II receptor 1; atrial cardiomyocyte; caveolin 3; transient outward potassium current (Ito)

Mesh:

Substances:

Year:  2021        PMID: 33416459      PMCID: PMC8082791          DOI: 10.1152/ajpheart.00569.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  40 in total

1.  Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

Authors:  P Paradis; N Dali-Youcef; F W Paradis; G Thibault; M Nemer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation.

Authors:  B J Brundel; I C Van Gelder ; R H Henning; R G Tieleman; A E Tuinenburg; M Wietses; J G Grandjean; W H Van Gilst ; H J Crijns
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

3.  Central role of PKCα in isoenzyme-selective regulation of cardiac transient outward current Ito and Kv4.3 channels.

Authors:  E P Scholz; F Welke; N Joss; C Seyler; W Zhang; D Scherer; M Völkers; R Bloehs; D Thomas; H A Katus; C A Karle; E Zitron
Journal:  J Mol Cell Cardiol       Date:  2011-07-22       Impact factor: 5.000

4.  Caveolae are essential for angiotensin II type 1 receptor-mediated ANP secretion.

Authors:  Young-Bin Oh; Shan Gao; Jung Min Lim; Hyung Tae Kim; Byung-Hyun Park; Suhn Hee Kim
Journal:  Peptides       Date:  2011-06-13       Impact factor: 3.750

Review 5.  Caveolins and cavins in the trafficking, maturation, and degradation of caveolae: implications for cell physiology.

Authors:  Anna R Busija; Hemal H Patel; Paul A Insel
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-25       Impact factor: 4.249

6.  Angiotensin II signal transduction pathways in the cardiovascular system.

Authors:  T B Rogers; A J Lokuta
Journal:  Trends Cardiovasc Med       Date:  1994 May-Jun       Impact factor: 6.677

7.  Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization.

Authors:  Sergey V Doronin; Irina A Potapova; Zhongju Lu; Ira S Cohen
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

8.  Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane.

Authors:  Bruce D Wyse; Ian A Prior; Hongwei Qian; Isabel C Morrow; Susan Nixon; Cornelia Muncke; Teymuras V Kurzchalia; Walter G Thomas; Robert G Parton; John F Hancock
Journal:  J Biol Chem       Date:  2003-04-13       Impact factor: 5.157

9.  Long QT syndrome caveolin-3 mutations differentially modulate Kv 4 and Cav 1.2 channels to contribute to action potential prolongation.

Authors:  Leonid Tyan; Jason D Foell; Kevin P Vincent; Marites T Woon; Walatta T Mesquitta; Di Lang; Jabe M Best; Michael J Ackerman; Andrew D McCulloch; Alexey V Glukhov; Ravi C Balijepalli; Timothy J Kamp
Journal:  J Physiol       Date:  2019-01-24       Impact factor: 5.182

10.  Stimulation of ICa by basal PKA activity is facilitated by caveolin-3 in cardiac ventricular myocytes.

Authors:  Simon Bryant; Tomomi E Kimura; Cherrie H T Kong; Judy J Watson; Anabelle Chase; M Saadeh Suleiman; Andrew F James; Clive H Orchard
Journal:  J Mol Cell Cardiol       Date:  2014-01-09       Impact factor: 5.000

View more
  2 in total

1.  Caveolin-3 prevents swelling-induced membrane damage via regulation of ICl,swell activity.

Authors:  Daniel G P Turner; Leonid Tyan; Frank C DeGuire; Roman Y Medvedev; Sami J Stroebel; Di Lang; Alexey V Glukhov
Journal:  Biophys J       Date:  2022-04-02       Impact factor: 3.699

Review 2.  Caveolin-3 and Arrhythmias: Insights into the Molecular Mechanisms.

Authors:  Miaomiao He; Jie Qiu; Yan Wang; Yang Bai; Guangzhi Chen
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.